Holen Sie sich die Stockscreener-App
20.73
0.44%
0.09
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India
Enliven grosses $230M from stock sale - BizWest
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Eastern Progress
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - MSN
Enliven Raises $230m To Fund Scemblix Leukemia Challenger - insights.citeline.com
Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst Upgrade - Defense World
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
Enliven Therapeutics Closes Public Offering - MarketScreener
Biotech Enliven Therapeutics Secures Massive $230M Funding Through Oversubscribed Public Offering - Stock Titan
Form 424B5 Enliven Therapeutics, - StreetInsider
Enliven (ELVN) Gains Buy Rating from Goldman Sachs with $37 Price Target | ELVN Stock News - GuruFocus
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down – Should You Sell? - Defense World
Enliven (ELVN) Initiates $200M Public Stock Offering | ELVN Stoc - GuruFocus
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The Malaysian Reserve
Enliven Therapeutics prices $200 million public offering By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc (ELVN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Enliven to sell $200M in stock after positive drug trial - BizWest
Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants - Nasdaq
Enliven Therapeutics prices $200 million public offering - Investing.com
Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs - Stock Titan
Enliven Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares - Nasdaq
Enliven Therapeutics Launches $200 Million Securities Offering - marketscreener.com
Enliven Therapeutics Announces Positive Phase 1 Trial Results - TipRanks
Enliven Therapeutics announces $200 million public offering - Investing.com
SEC Form 424B5 filed by Enliven Therapeutics Inc. - Quantisnow
Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option - Stock Titan
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire
California State Teachers Retirement System Buys 1,940 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% After Insider Selling - Defense World
Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView
Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World
Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail
Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World
Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia
Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust Corp - Defense World
HC Wainwright Issues Pessimistic Outlook for ELVN Earnings - Defense World
Jones Trading Has Lowered Expectations for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Q1 Earnings Forecast for ELVN Issued By HC Wainwright - Defense World
HC Wainwright Raises Enliven Therapeutics (NASDAQ:ELVN) Price Target to $40.00 - Defense World
Jones Trading Lowers Price Target for Enliven Therapeutics (ELVN) | ELVN Stock News - GuruFocus
Enliven (ELVN) Stock Target Cut Amid Mixed Market Reaction | ELVN Stock News - GuruFocus
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Holdings Lifted by Price T Rowe Associates Inc. MD - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 7.6% Following Weak Earnings - Defense World
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):